Psilocybin therapy

NeonMind Engages Pharma Executive Philippe Martin to Advance its Psilocybin Drug Candidates for Obesity

Retrieved on: 
Tuesday, March 9, 2021
Psychoactive drugs, Entheogens, Drug discovery, Organophosphates, Mycotoxins, Psilocybin, Psychedelic drug, Drug development, Psychedelic therapy, Psilocybin therapy

NeonMind has engaged Mr. Martin to advise on drug development programs and recommend critical resources for execution, as well as review and evaluate potential drug development paths to advance NeonMind's two psilocybin drug development programs.

Key Points: 
  • NeonMind has engaged Mr. Martin to advise on drug development programs and recommend critical resources for execution, as well as review and evaluate potential drug development paths to advance NeonMind's two psilocybin drug development programs.
  • NeonMind's first drug candidate aims to use synthetic psilocybin to enhance a patient's ability to alter behaviours that cause weight loss through psychedelic-assisted cognitive therapy.
  • The second drug candidate offers low dose synthetic psilocybin as a treatment to suppress appetite.
  • "Philippe will help us navigate the many decisions we need to make to advance synthetic psilocybin through the rigorous drug development process towards becoming an approved medical therapy."

COMPASS Pathways announces publication in Frontiers in Psychiatry of paper on therapist training programme for psilocybin therapy

Retrieved on: 
Wednesday, February 3, 2021
Psychoactive drugs, Entheogens, Psychoactive fungi, Psilocybe, Psilocybin therapy, Psilocybin, Psychedelic drug, Psychedelic therapy, Psilocybin mushroom

The programme sets out a formal and scalable methodology for psychological support in psilocybin therapy.

Key Points: 
  • The programme sets out a formal and scalable methodology for psychological support in psilocybin therapy.
  • In psilocybin therapy, patients are given a dose of psilocybin, a psychedelic substance, in conjunction with psychological support from specially trained therapists.
  • We will continue to evolve our training programme as we progress COMP360 psilocybin therapy through clinical trials.
  • We hope that this first step encourages collaboration among therapist training providers, as we work towards bringing psilocybin therapy to all who might benefit.

Research and Development Moves the Psychedelics Market Forward

Retrieved on: 
Wednesday, January 27, 2021
Psychoactive drugs, Entheogens, Mycotoxins, Organophosphates, Psilocybin, Psychedelic drug, Psilocybin therapy, Multidisciplinary Association for Psychedelic Studies

As a leading company in the psychedelic biotech and life sciences space, Mydecine has had a large role on the research and development as well as the commercialization front.

Key Points: 
  • As a leading company in the psychedelic biotech and life sciences space, Mydecine has had a large role on the research and development as well as the commercialization front.
  • Mydecine has also signed on for a partnership agreement with Applied Pharmaceutical Innovation to advance its research and development efforts for mental health care solutions.
  • Numinus says that this state-of-the-art instrument will accelerate the company's psychedelic standardized testing, as well as its research and development.
  • Alphamind has been developing several psilocybin-based products in addition to conducting research and development for psilocybin pharmaceutical applications.

Research and Development Moves the Psychedelics Market Forward

Retrieved on: 
Wednesday, January 27, 2021
Psychoactive drugs, Entheogens, Mycotoxins, Organophosphates, Psilocybin, Psychedelic drug, Psilocybin therapy, Multidisciplinary Association for Psychedelic Studies

As a leading company in the psychedelic biotech and life sciences space, Mydecine has had a large role on the research and development as well as the commercialization front.

Key Points: 
  • As a leading company in the psychedelic biotech and life sciences space, Mydecine has had a large role on the research and development as well as the commercialization front.
  • Mydecine has also signed on for a partnership agreement with Applied Pharmaceutical Innovation to advance its research and development efforts for mental health care solutions.
  • Numinus says that this state-of-the-art instrument will accelerate the company's psychedelic standardized testing, as well as its research and development.
  • Alphamind has been developing several psilocybin-based products in addition to conducting research and development for psilocybin pharmaceutical applications.

Further Research into Psilocybin Opens New Doors for Treatment

Retrieved on: 
Thursday, January 7, 2021
Entheogens, Psychoactive fungi, Psychoactive drugs, Fungi, Branches of biology, Psilocybin mushroom, Psilocybin, Psychedelic drug, Mushroom, Psychedelic therapy, Psilocybin therapy

Also, in 2019, the FDA awarded the second Breakthrough Therapy designation to non-profit Usona Institute, which is studying the effects of psilocybin as an anti-depressant.

Key Points: 
  • Also, in 2019, the FDA awarded the second Breakthrough Therapy designation to non-profit Usona Institute, which is studying the effects of psilocybin as an anti-depressant.
  • Psilocybin is a naturally occurring psychedelic compound produced by more than 200 species of mushrooms, collectively known as psilocybin mushrooms.
  • 'Our focus of the study is exploring whether microdosing leads to changes in novelty perception or pattern recognition,' said Dr. Polito.
  • Dr. Polito is a Research Fellow in the Department of Cognitive Science at Macquarie University.

Further Research into Psilocybin Opens New Doors for Treatment

Retrieved on: 
Thursday, January 7, 2021
Entheogens, Psychoactive fungi, Psychoactive drugs, Fungi, Branches of biology, Psilocybin mushroom, Psilocybin, Psychedelic drug, Mushroom, Psychedelic therapy, Psilocybin therapy

Also, in 2019, the FDA awarded the second Breakthrough Therapy designation to non-profit Usona Institute, which is studying the effects of psilocybin as an anti-depressant.

Key Points: 
  • Also, in 2019, the FDA awarded the second Breakthrough Therapy designation to non-profit Usona Institute, which is studying the effects of psilocybin as an anti-depressant.
  • Psilocybin is a naturally occurring psychedelic compound produced by more than 200 species of mushrooms, collectively known as psilocybin mushrooms.
  • 'Our focus of the study is exploring whether microdosing leads to changes in novelty perception or pattern recognition,' said Dr. Polito.
  • Dr. Polito is a Research Fellow in the Department of Cognitive Science at Macquarie University.

New Wave Holdings Congratulates TheraPsil's Advocacy to Bring Psilocybin Therapy to Palliative Care for Canadian Patients

Retrieved on: 
Thursday, December 10, 2020
Psychoactive drugs, Health sciences, Entheogens, Psilocybe, Psilocybin therapy, Drug discovery, Psychoactive fungi, Psilocybin, Therapy, Legal status of psilocybin mushrooms, Psilocybin decriminalization in the United States

17 healthcare professionals associated with TheraPsil, a non-profit, patient-rights advocacy group, have been approved by the Federal Health Minister, Patty Hajdu, to possess and use psilocybin for professional training in psilocybin therapy.

Key Points: 
  • 17 healthcare professionals associated with TheraPsil, a non-profit, patient-rights advocacy group, have been approved by the Federal Health Minister, Patty Hajdu, to possess and use psilocybin for professional training in psilocybin therapy.
  • New Wave is proud to have sponsored TheraPsil in this journey and applaud the hard work conducted by the team and all the various partners involved.
  • TheraPsil is a non-profit coalition that advocates for legal, compassionate access to psilocybin therapy for Canadians in medical need.
  • TheraPsil, supports patients with their applications for ministerial approval of psilocybin for medical purposes and connects approved patients with qualified practitioners to receive psilocybin-assisted therapy treatment.

New Study Finds Psychedelic Treatments More Effective than Typical Antidepressant Medications

Retrieved on: 
Friday, November 13, 2020
Branches of biology, Mind, Psychiatric diagnosis, Abnormal psychology, Entheogens, Antidepressant, Major depressive disorder, Mental disorder, Psilocybin, Hallucinogen, Psychiatry, Psilocybin therapy

To view the full editorial, please visit: https://nnw.fm/kdV3F

Key Points: 
  • To view the full editorial, please visit: https://nnw.fm/kdV3F
    Earlier this month, an article in the journal JAMA Psychiatry reported the remarkable findings of a study featuring the hallucinogenpsilocybin.
  • The research team observed that the treatment had an effect more than four times greater than the typical antidepressant medications... .
  • The JAMA report noted that additional research and study on all aspects psilocybin is warranted, and Cybin Inc .
  • This could become a groundbreaking advancement not just for the delivery psilocybin therapeutics but also for more effective treatments of mental disorders.

Numinus Commences Psilocybe Mushroom Cultivation at its Health Canada Licensed Laboratory

Retrieved on: 
Thursday, September 24, 2020
Psychoactive drugs, Entheogens, Psychoactive fungi, Mycotoxins, Organophosphates, Psilocybin, Psychotherapy, Psychedelic drug, Legal status of psilocybin mushrooms, Psilocybin therapy

Psilocybin-assisted psychotherapy is currently being studied as a treatment for a range of mental health conditions including depression, anxiety, and substance use disorders.

Key Points: 
  • Psilocybin-assisted psychotherapy is currently being studied as a treatment for a range of mental health conditions including depression, anxiety, and substance use disorders.
  • Under its Health Canada licence for the production and extraction of psilocybin from mushrooms, Numinus intends to cultivate and harvest the mushrooms for a variety of purposes including:
    "We are thrilled to start growing mushrooms at our laboratory under our Health Canada licence," says Michael Tan, Chief Operating Officer.
  • Numinus' vertically integrated ecosystem positions the Company to be a first-in-market, trusted leader in the delivery of psychedelic-assisted psychotherapies when regulated.
  • Numinus' ecosystem units include Numinus Bioscience, Numinus R&D, and Numinus Health.

Ehave, Inc. Announces Psychedelic Retreats Through Its Mycotopia Therapy Subsidiary

Retrieved on: 
Friday, August 28, 2020
Health sciences, Health, Drug discovery, Medicine, Hallucinations, Psychedelic therapy, Psychedelic drug, Drug culture, Drug, Therapy, Multidisciplinary Association for Psychedelic Studies, Psilocybin therapy

Ehave partner MyLifeID, which is a licensed medical travel agency, will serve as booking agent for the psychedelic retreats.

Key Points: 
  • Ehave partner MyLifeID, which is a licensed medical travel agency, will serve as booking agent for the psychedelic retreats.
  • Mycotopia Therapy will be offering its psilocybin-guided wellness retreats at five-star locations around the world.
  • Psychedelic retreats are not recreational drug use, but rather an opportunity to use psychedelics as self-exploratory and therapeutic plant medicine.
  • Psychedelic therapy is a holistic and spiritual approach providing healing and has shown successful treatment for many years.